$4.85 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 127 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 88.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | GLAUKOS CORPnote 2.750% 6/1 | $324,465,000 | -9.6% | 271,752,000 | +0.7% | 6.69% | -16.6% | |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $196,199,000 | +26.2% | 2,012,714 | +21.4% | 4.05% | +16.5% |
| New | IONIS PHARMACEUTICALS INCnote 4/0 | $116,991,000 | – | 127,800,000 | +100.0% | 2.41% | – | |
| BIIB | New | BIOGEN INCcall | $101,970,000 | – | 500,000 | +100.0% | 2.10% | – |
| SILK | Buy | SILK RD MED INC | $97,412,000 | +9.5% | 2,676,891 | +24.3% | 2.01% | +1.1% |
| Buy | TABULA RASA HEALTHCARE INCnote 1.750% 2/1 | $97,174,000 | +21.9% | 144,516,000 | +34.0% | 2.00% | +12.4% | |
| GILD | Buy | GILEAD SCIENCES INC | $95,969,000 | +110.9% | 1,552,639 | +102.8% | 1.98% | +94.6% |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $82,200,000 | +58.9% | 6,250,964 | +12.0% | 1.70% | +46.5% |
| IMGN | Buy | IMMUNOGEN INC | $67,592,000 | +309.2% | 15,020,490 | +332.8% | 1.39% | +277.8% |
| DAWN | Buy | DAY ONE BIOPHARMACEUTICALS I | $62,867,000 | +203.7% | 3,512,123 | +68.3% | 1.30% | +180.1% |
| New | ACCOLADE INCnote 0.500% 4/0 | $59,134,000 | – | 92,624,000 | +100.0% | 1.22% | – | |
| New | GUARDANT HEALTH INCnote 11/1 | $56,684,000 | – | 89,036,000 | +100.0% | 1.17% | – | |
| COGT | Buy | COGENT BIOSCIENCES INC | $53,009,000 | +342.1% | 5,876,805 | +267.1% | 1.09% | +307.8% |
| ISEE | Buy | IVERIC BIO INC | $50,159,000 | -39.1% | 5,214,000 | +6.6% | 1.04% | -43.8% |
| CNC | Buy | CENTENE CORP DEL | $48,972,000 | +5.0% | 578,800 | +4.5% | 1.01% | -3.1% |
| New | OAK STR HEALTH INCnote 3/1 | $48,551,000 | – | 68,000,000 | +100.0% | 1.00% | – | |
| GKOS | Buy | GLAUKOS CORP | $47,215,000 | +121.0% | 1,039,514 | +181.3% | 0.97% | +103.8% |
| MOH | Buy | MOLINA HEALTHCARE INC | $46,695,000 | +3.7% | 167,000 | +23.7% | 0.96% | -4.4% |
| CYTK | Buy | CYTOKINETICS INC | $45,589,000 | +30.0% | 1,160,315 | +21.8% | 0.94% | +19.9% |
| MRUS | Buy | MERUS N V | $44,961,000 | +289.1% | 1,985,924 | +354.4% | 0.93% | +259.3% |
| New | DYNAVAX TECHNOLOGIES CORPnote 2.500% 5/1 | $44,735,000 | – | 30,000,000 | +100.0% | 0.92% | – | |
| New | LIVONGO HEALTH INCnote 0.875% 6/0 | $42,380,000 | – | 50,000,000 | +100.0% | 0.87% | – | |
| EOLS | Buy | EVOLUS INC | $42,140,000 | +205.5% | 3,632,751 | +195.5% | 0.87% | +182.1% |
| Buy | 1LIFE HEALTHCARE INCnote 3.000% 6/1 | $40,222,000 | +15.9% | 48,599,000 | +21.5% | 0.83% | +7.0% | |
| BKD | Buy | BROOKDALE SR LIVING INC | $39,010,000 | +2.9% | 8,592,461 | +59.7% | 0.80% | -5.1% |
| New | PTC THERAPEUTICS INCnote 1.500% 9/1 | $33,439,000 | – | 32,000,000 | +100.0% | 0.69% | – | |
| New | HILLEVAX INC | $28,614,000 | – | 2,617,948 | +100.0% | 0.59% | – | |
| Buy | PTC THERAPEUTICS INCnote 3.000% 8/1 | $25,518,000 | +69.3% | 25,417,000 | +75.0% | 0.53% | +56.1% | |
| Buy | SEMA4 HOLDINGS CORP | $23,749,000 | -44.1% | 18,848,488 | +36.1% | 0.49% | -48.4% | |
| PHR | New | PHREESIA INC | $21,436,000 | – | 857,115 | +100.0% | 0.44% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $21,378,000 | – | 1,111,111 | +100.0% | 0.44% | – |
| AMED | New | AMEDISYS INC | $20,919,000 | – | 199,000 | +100.0% | 0.43% | – |
| TARS | New | TARSUS PHARMACEUTICALS INC | $19,334,000 | – | 1,324,214 | +100.0% | 0.40% | – |
| INSM | Buy | INSMED INC | $18,941,000 | +164.6% | 960,484 | +215.4% | 0.39% | +144.4% |
| Buy | THE ONCOLOGY INSTITUTE INC | $17,118,000 | -46.7% | 3,383,099 | +2.6% | 0.35% | -50.8% | |
| PCRX | New | PACIRA BIOSCIENCES INC | $17,024,000 | – | 292,000 | +100.0% | 0.35% | – |
| ANAB | New | ANAPTYSBIO INC | $15,672,000 | – | 772,000 | +100.0% | 0.32% | – |
| INZY | Buy | INOZYME PHARMA INC | $12,862,000 | +34.1% | 2,696,372 | +15.0% | 0.26% | +23.8% |
| KZR | New | KEZAR LIFE SCIENCES INC | $11,735,000 | – | 1,419,000 | +100.0% | 0.24% | – |
| TGTX | New | TG THERAPEUTICS INC | $11,379,000 | – | 2,677,500 | +100.0% | 0.24% | – |
| FHTX | Buy | FOGHORN THERAPEUTICS INC | $10,574,000 | +190.7% | 777,525 | +225.5% | 0.22% | +169.1% |
| New | PEPGEN INC | $9,470,000 | – | 953,626 | +100.0% | 0.20% | – | |
| NKTX | New | NKARTA INC | $7,392,000 | – | 600,000 | +100.0% | 0.15% | – |
| New | BENEFITFOCUS INCnote 1.250%12/1 | $5,907,000 | – | 6,500,000 | +100.0% | 0.12% | – | |
| Buy | AN2 THERAPEUTICS INC | $5,553,000 | -36.9% | 716,538 | +22.7% | 0.12% | -41.6% | |
| New | NEOGENOMICS INCnote 1.250% 5/0 | $5,443,000 | – | 6,500,000 | +100.0% | 0.11% | – | |
| ETNB | New | 89BIO INC | $1,630,000 | – | 506,100 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.